Author's reply to Keatinge and Wong and Cruickshank by Møller, Henrik
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/bmj.h5903
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Møller, H. (2015). Author's reply to Keatinge and Wong and Cruickshank. BMJ (Clinical research ed.), 351,
[h5903]. 10.1136/bmj.h5903
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
URGENT CANCER REFERRAL PATHWAY
Author’s reply to Keatinge andWong andCruickshank
Henrik Møller professor of cancer epidemiology
Cancer Epidemiology and Population Health, King’s College London, London SE1 9RT, UK
We appreciate the interest and debate that our article has
generated in rapid responses and conferences and workshops
in the past year.1-3 We too thought that the press headlines
(mainly arising from a single press agency) were sensationalist
and unhelpful.
The concern about lead time contributing to the observed
association between urgent referral and patient survival is valid
and is covered in the paper’s discussion. Lead time is unlikely
to be the single cause of the survival difference, and there is
evidence that the use of urgent referral is associated with a
favourable stage distribution.4 This implies that GPs’ awareness
of cancer and their propensity to use urgent referral is important;
this is also illustrated by our finding (web appendix) that cancer
patients from practices with many old patients have better age
adjusted survival than those from practices with younger
patients.
We agree that the results of the overall analysis of all types of
cancer do not necessarily apply to each of the less common
types of cancer.
Prostate cancer kills more than 10 000 UK men each year and
the importance of referral and early diagnosis should not be
dismissed.
Our conclusion that “General practices that consistently have a
low propensity to use urgent referrals could consider increasing
their use of this pathway, thereby plausibly increasing the
survival of their patients with cancer” was not meant to advocate
excessive use of urgent referral. The statement is consistent with
the recently updated NICE guidance.5 A single research article
cannot be authoritative regarding the use of urgent referral—GPs
should look to the NICE guidance for such advice.
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